<?xml version='1.0' encoding='utf-8'?>
<document id="24220936"><sentence text="Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer."><entity charOffset="38-48" id="DDI-PubMed.24220936.s1.e0" text="vinflunine" /><entity charOffset="69-78" id="DDI-PubMed.24220936.s1.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.24220936.s1.e0" e2="DDI-PubMed.24220936.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24220936.s1.e0" e2="DDI-PubMed.24220936.s1.e1" /></sentence><sentence text="Erlotinib, the epidermal growth factor receptor tyrosine kinase inhibitor, and the intra-venous vinflunine vinca alkaloid microtubule inhibitor have been shown to be effective in the setting of non-small-cell lung cancer (NSCLC) palliative patients with acceptable toxicities"><entity charOffset="0-9" id="DDI-PubMed.24220936.s2.e0" text="Erlotinib" /><entity charOffset="48-56" id="DDI-PubMed.24220936.s2.e1" text="tyrosine" /><entity charOffset="96-106" id="DDI-PubMed.24220936.s2.e2" text="vinflunine" /><entity charOffset="113-121" id="DDI-PubMed.24220936.s2.e3" text="alkaloid" /><pair ddi="false" e1="DDI-PubMed.24220936.s2.e0" e2="DDI-PubMed.24220936.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24220936.s2.e0" e2="DDI-PubMed.24220936.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24220936.s2.e0" e2="DDI-PubMed.24220936.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24220936.s2.e0" e2="DDI-PubMed.24220936.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24220936.s2.e1" e2="DDI-PubMed.24220936.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24220936.s2.e1" e2="DDI-PubMed.24220936.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24220936.s2.e1" e2="DDI-PubMed.24220936.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24220936.s2.e2" e2="DDI-PubMed.24220936.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24220936.s2.e2" e2="DDI-PubMed.24220936.s2.e3" /></sentence><sentence text=" This phase I study was conducted to determine the maximal tolerated dose (MTD) and the safety of an all-oral combination" /><sentence text=" A potential pharmacokinetic drug-drug interaction was also investigated" /><sentence text="" /><sentence text="Patients with unresectable stage IIIB or stage IV NSCLC who failed one or two previous chemotherapy regimens were treated with flat doses of oral vinflunine from day 1 to day 5 and from day 8 to day 12 every 3 weeks and erlotinib daily on a continuous basis"><entity charOffset="146-156" id="DDI-PubMed.24220936.s6.e0" text="vinflunine" /><entity charOffset="220-229" id="DDI-PubMed.24220936.s6.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.24220936.s6.e0" e2="DDI-PubMed.24220936.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24220936.s6.e0" e2="DDI-PubMed.24220936.s6.e1" /></sentence><sentence text=" The dose levels of vinflunine/erlotinib were 95/100, 115/100, 115/150 and 135/100 mg"><entity charOffset="20-30" id="DDI-PubMed.24220936.s7.e0" text="vinflunine" /><entity charOffset="31-40" id="DDI-PubMed.24220936.s7.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.24220936.s7.e0" e2="DDI-PubMed.24220936.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24220936.s7.e0" e2="DDI-PubMed.24220936.s7.e1" /></sentence><sentence text="" /><sentence text="Thirty patients were enroled" /><sentence text=" The recommended dose was 115/150 mg and the MTD 135/100 mg" /><sentence text=" Dose-limiting toxicities included grade 3 febrile neutropenia (1 patient) and related death (1 patient)" /><sentence text=" Non-haematologic grade 3/4 toxicities included fatigue, condition aggravated, hypokalaemia, tumour pain, acneiform dermatitis, diarrhoea, hyperbilirubinaemia and pulmonary haemorrhage, in one patient each" /><sentence text=" Of 25 patients evaluable for tumour response, 2 patients had partial response and 20 patients had stable disease" /><sentence text="" /><sentence text="The recommended doses for oral vinflunine and erlotinib combination were, respectively, 115 mg/day from day 1 to day 5 and from day 8 to day 12 every 3 weeks and 150 mg/day"><entity charOffset="31-41" id="DDI-PubMed.24220936.s15.e0" text="vinflunine" /><entity charOffset="46-55" id="DDI-PubMed.24220936.s15.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.24220936.s15.e0" e2="DDI-PubMed.24220936.s15.e0" /><pair ddi="false" e1="DDI-PubMed.24220936.s15.e0" e2="DDI-PubMed.24220936.s15.e1" /></sentence><sentence text=" There was no mutual impact on pharmacokinetics" /><sentence text=" The combination was safe but evaluation in phase II is needed to further refine the activity and toxicity that can be expected with prolonged administration of this dose schedule" /><sentence text="" /></document>